Hear 20+ Presentations from Top Pharma at Drug Discovery Chemistry

As in the past, speaker participation by industry is once again very strong, with presentations from AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Eli LillyF. Hoffmann-La Roche, Genentech, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Sanofi. Preview the more than 20 presentations* below:


Utilization of a Fragment-based Approach in the Development of Orally Efficacious TNFα Inhibitors

Justin Dietrich, PhD, Principal Research Scientist I, Fragment Based Drug Discovery and DNA-Encoded Library Technologies



Scaffold Selection for Protein-Protein Interaction Modulation: Are There Any General Principles?

Leonardo De Maria, PhD, Principal Scientist


Structure-Free Elaboration of Fragments into Novel Allosteric MEK1 Binders

Paolo Di Fruscia, PhD, Senior Research Scientist, Medicinal Chemistry


Profiling of Covalent Inhibitors Using Biophysical Approaches

Stefan Geschwindner, Associate Director & Head of Biophysics


Turning Linear Peptide Substrates into Macrocyclic Inhibitors

Ranganath Gopalakrishnan, PhD, Associate Principal Scientist, New Modality & Medicinal Chemistry



Discovering New Protein Interaction Partners of Gamma-Secretase with Photoaffinity Probes

Doug Johnson, PhD, Senior Director, Chemical Biology & Proteomics


Chemoproteomic Profiling of Covalent XPO1 Inhibitors to Assess Target Engagement and Selectivity

Jeffrey Martin, PhD, Scientist II, Drug Discovery


Boehringer Ingelheim

Evolution of BI-3406 – Getting a Foot in the Door between SOS1 and KRAS

Juergen Ramharter, PhD, Principal Scientist & Project Lead, Oncology Research


Eli Lilly & Co.

eDESIGNER: A Tool for Navigating the DNA-Encoded Libraries Chemical Space

Alfredo Martin, PhD, Senior Research Advisor, DCRT


F. Hoffmann-La Roche AG

Discovery of Novel g-Secretase Modulators (GSM) for the Potential Treatment of Alzheimer’s Disease

Hasane Ratni, PhD, Distinguished Scientist & Project Team Leader, Medicinal Chemistry


Genentech Inc.

Cyanopyrrolidine Inhibitors of USP7 Mediate Desulfhydration of the Active-Site Cysteine

Charlene Bashore, PhD, Principal Scientific Researcher


What Is AI Good for in Small Molecule Drug Discovery?

Jeff Blaney, Director Computational Chemistry & Cheminformatics, Computational Chemistry & Cheminformatics


Hijacking Autophagy by Co-Opting LC3 with Fragment Derived Ligands

Micah Steffek, MSc, Principal Scientific Researcher, Biochemical & Cellular Pharmacology



Discovery of Small Molecule Inhibitors of sEH and RIPK1 Enabled by DNA-Encoded Library Technology: Two Case Studies

Carol Mulrooney, PhD, Investigator, Cheminformatics


Merck & Co., Inc.

An Orally Available Non-Nucleotide STING Agonist with Antitumor Activity: A Mechanistic Study

Gottfried Schroeder, PhD, Senior Scientist, Quantitative Biosciences



Enabling Comprehensive and High-Throughput Exploration of Fragment Chemical Space by Using Broadband 19F NMR-Based Screening

Andreas Lingel, PhD, Senior Principal Scientist, Global Discovery Chemistry, NIBR


Characterization of the Recruitment of Proteins to Ligases by Molecular Glues

Charles A. Wartchow, PhD, Senior Principal Scientist, Global Discovery Chemistry, NIBR


Pfizer Inc.

Targeted Protein Degradation – Where Are We Going?

Adam Gilbert, PhD, Senior Director, Discovery Sciences, Design & Synthesis Sciences


Toward the Assembly and Characterization of an Encoded Library Hit Optimization Platform: Bead-Assisted Ligand Isolation for Mass Spectrometry (BALI-MS)

Anokha S. Ratnayake, PhD, Principal Scientist, Design and Synthesis Sciences, DNA Encoded Library Technology Group


Determining Affinity from Irreversible Thermal Shift

Justin Hall, PhD, Principal Scientist, Structural Biology & Biophysics



Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins

Stefan Guessregen, PhD, Principal Scientist, R&D Integrated Drug Discovery

* As of 3/10/21 – Please see individual agenda pages for most up-to-date list of speakers